P27 Expression in Endothelin-1 Stimulated Mitogenesis by Kiriu, Joseph
Western Kentucky University
TopSCHOLAR®
Masters Theses & Specialist Projects Graduate School
8-1-2007
P27 Expression in Endothelin-1 Stimulated
Mitogenesis
Joseph Kiriu
Western Kentucky University
Follow this and additional works at: http://digitalcommons.wku.edu/theses
Part of the Medical Sciences Commons
This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Masters Theses & Specialist Projects by
an authorized administrator of TopSCHOLAR®. For more information, please contact connie.foster@wku.edu.
Recommended Citation
Kiriu, Joseph, "P27 Expression in Endothelin-1 Stimulated Mitogenesis" (2007). Masters Theses & Specialist Projects. Paper 428.
http://digitalcommons.wku.edu/theses/428
P27 Expression in Endothelin-1 Stimulated Mitogenesis 
A thesis 
Presented to 
The graduate faculty of the of Department Biology 
Western Kentucky University 
In partial fulfillment 
Of the requirements for the degree of 
Master of Science in Biology 
Joseph Kirui 
August, 2007 
1 
APPROVAL 
This thesis has been read by each member of the thesis committee and has been 
found to be satisfactory regarding content, English usage, format, citations, bibliographic 
style, and consistency, and is ready for submission to the College of Graduate Studies. 
Date Recommended . C.J Zo°7-
Director of Thesis 
Dean, Graduate Studies and Research Date 
3 
DEDICATION 
This work is dedicated to my dear parents, Mr. and Mrs. Andrew Siele, my 
Wife, Mercy, and our little son Jacob who have been a source of encouragement and 
support of my graduate work. 
4 
ACKNOWLEDGEMENTS 
This thesis would not have been possible without the assistance and 
encouragement of many people. Primarily, I am thankful to Dr. Ken Crawford the major 
advisor who through his tireless efforts provided assistance with academic as well as non-
academic problems, and provided funding for this project. I am indebted to Dr Cheryl 
Davis and Dr Sigrid Jacobshagen for her enormous support and useful suggestions in 
making this a reality. I Thank Dr Nancy Rice for providing material support (antibodies 
and ECF reagent). The head of the biology department, Dr Richard Bowker and 
departmental staff are thankfully acknowledged for their support. 
5 
TABLE OF CONTENTS 
Acknowledgements 4 
Table of Contents 5 
Abstract 6 
Introduction & Background information 
Cornea 7 
Corneal endothelium 9 
Cell cycle 10 
Important regulatory proteins in cell cycle 11 
P27 13 
Endothelin 14 
Hypothesis 17 
Methodology 18 
Results 22 
Discussion 29 
Conclusion 32 
Bibliography 33 
6 
ABSTRACT 
Bovine corneal endothelial cells (BCECs) have been shown in our lab to 
synthesize and secrete endothelin-1 (ET-1). The endothelin-1 binds ETA receptors, this 
elevates intracellular calcium, stimulate DNA replication and cell division. This 
investigation explores ET-l 's role as a mitogenic factor in corneal endothelial cells and 
addresses whether mitogenic activity is mediated through the cyclin dependent kinase 
inhibitor p27. BCEC were isolated from bovine eyes and grown in DMEM-10% serum 
in a 5% C02 , 37° C incubator. Confluent cultures of BCEC were incubated for 24 hours 
with lOOnM Endothelin-1, luM BQ123 and BQ123 +100nM Endothelin-1 and some left 
untreated. Total cellular protein was isolated and the concentration quantified by the 
Peterson modification of the Lowry protein assay. Protein samples and prestained 
molecular weight standards were separated by 4-15% gradient SDS-PAGE and 
transferred overnight to PVDF Hyperbond membrane by western blot. The relative 
abundance of p27 was detected using a polyclonal antibody for p27 (1:100) and HRP 
conjugated secondary antibody (1:500) and alkaline phosphatase conjugated secondary 
antibody (goat-anti rabbit). The membrane was then washed thoroughly with PBST and 
treated with enhanced chemiluminescence (ECL) or enhanced chemifluorescence (ECF). 
The data show a marked decrease in cellular p27 in cells treated with 1 OOnM endothelin-
1. ET-1 appears to have mitogenic properties in BCEC by downregulating the expression 
of p27. Stimulation of cell proliferation may be mediated by suppressing the expression 
of p27, a cyclin dependent kinase inhibitor. 
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CHAPTER 1 
Introduction 
The Cornea 
The cornea is a transparent dome shaped window that covers the anterior of the 
eye. It is a highly organized group of cells and proteins that is smooth and clear but 
strong and durable. The cornea receives its nourishment from tears and aqueous humor 
that fills the chamber behind it. The cornea must remain transparent to refract light 
properly. To see well, all of the cornea must be free of any particles, which prevent light 
from reaching retina (1). The corneal organ is comprised of five layers, each having a 
distinct function. The outermost layer is the stratified epithelium which comprises 
approximately ten percent of the tissue's thickness. Its main function is to block the 
passage of microorganisms and nonliving particles into the eye. It also provides a smooth 
surface for absorption and distribution of oxygen and cell nutrients to the rest of the 
cornea. The epithelium also acts as a sensory tissue; it is filled with thousands of tiny 
nerve endings that make the cornea extremely sensitive when rubbed or scratched. The 
epithelium possesses a basement membrane which serves as foundation on which the 
epithelial cells anchor and organize themselves. Lying below this membrane is a 
transparent sheet of tissue known as Bowman's layer, which is composed of collagen 
(strong layered protein fibers). If the Bowman's layer is injured, it can form a scar as it 
heals, and this scarring can result in vision loss. 
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Beneath the Bowman's layer is the stroma, which comprises about 90% of 
cornea's thickness. It consists of water (about 78%) and collagen (about 16%); its main 
function is to give the cornea strength, elasticity and form. Collagen's unique shape, 
arrangement and spacing are essential in producing light-conducting transparency. Under 
the stroma is Descemet's membrane, which is a thin but strong sheet of tissue that serves 
as a protective barrier against infection and injuries. The Descemet's membrane is made 
by the endothelial cells that lie below; these endothelial cells, collectively called an 
endothelium, form the innermost layer of cornea. 
9 
Corneal Endothelium 
The corneal endothelium is a single layer of cells located at posterior of the 
cornea. The chief function of the corneal endothelium is to maintain corneal transparency 
(2). As fluids leak slowly from the aqueous humor into the stroma, the endothelium 
pumps this excess fluid out of the stroma (1, 4). Without the pumping action, the stroma 
would swell with water, and become hazy and eventually opaque. A healthy eye 
maintains a perfect balance between the fluids moving in and out of the cornea. In the 
early stages of corneal development, the endothelial cells actively divide to form the 
endothelium (3). When these cells mature they establish the gap and tight junctions, 
which results in the cessation of proliferation. The endothelial density decreases with age 
(4), and this loss is further accelerated by disease (5). The capacity of the corneal 
endothelium to regenerate is severely limited in man and other primates (3,4). Thus 
corneal wound repair is achieved primarily by cell enlargement and by redistributing 
existing cells (4). It is not clear why corneal endothelium exhibits limited capacity to 
proliferate, but molecular events governing the cell cycle may play a role (4, 6). Recent 
findings on the expression of cell cycle associated proteins in donor human corneas 
suggest that human corneal endothelial have not exited the cell cycle but are arrested in 
G-l phase, suggesting these cells could possess proliferative potential (6). 
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The Cell Cycle 
The cell cycle is a series of events in a eukaryotic cell between one cell division 
and the next. It consists of four phases: the G1 phase, the S phase the G2 phase (together 
these phases are called interphase) and the M phase. The M phase is composed of two 
tightly coupled processes: Mitosis and cytokinesis. In mitosis the cell's chromosomes are 
replicated and divided between the two daughter cells. In cytokinesis the cell cytoplasm 
physically divides. Cells that have temporarily stopped dividing are said to be in a state of 
quiescence (also called Go phase), while cells that have permanently stopped dividing due 
to age or accumulated DNA damage are said to be senescent. The cell cycle coordinates 
events needed for the growth of all eukaryotic cells. Events such as DNA replication (S-
phase) and cell division (M-phase) occur in the right temporal sequence and proceed in 
an orderly fashion (7). In addition, the cell cycle receives and integrates signals from 
diverse growth regulatory pathways, ensuring that the cell grows only in the presence of 
the appropriate signals and in the right environment (8). There are two key classes of 
regulatory molecules that determine cell's progress through the cell cycle: cyclins and 
cyclin dependent kinase. 
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Important regulatory proteins in the cell cycle 
In mammalian cell division, the progression through the first gap phase (Gl) of the 
cell cycle and the initiation of DNA synthesis (S phase), of which are mitogen-dependent, 
are cooperatively regulated by several classes of cyclins and cyclin dependent kinases 
(CDKs) (8). Cyclins control the progression of cells through the phases of the cell cycle 
by forming complexes with cyclin dependent kinases (CDKs). The CDKs are a family of 
heterodimeric serine/threonine protein kinases, each consisting of a catalytic CDK 
subunit and an activating cyclin subunit. In most eukaryotes, there are different CDKs 
that control the different stages of the cell cycle. They coordinate the cell cycle by acting 
as on and off switches (7). When a CDK is on, the cell cycle progresses through the stage 
that particular CDK controls. When a CDK is off, cell cycle stops when it reaches the 
stage controlled by that particular CDK (7, 8). 
Regulation of cyclin-CDKs complexes occurs at multiple levels, including the 
assembly of cyclin and CDK. Cyclins are the regulatory subunits of these complexes, and 
the enzymatic activity of CDK is dependent on physical interaction with one of the cyclin 
proteins. In addition, CDK activity can be negatively regulated by a group of proteins 
collectively termed CDK inhibitors (CDKIs) (5). The CDKIs are a newly recognized 
family of proteins (7) and are well characterized for their role as negative regulators of 
the G-l phase of the cell cycle (9). CDKIs that govern these events have been assigned 
to one of two families based on their structures and CDK targets. The first family 
includes the INK4 proteins (inhibitors of CDK4). The inhibitors work by binding to 
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CDK4 and CDK6 (8); they bind isolated CDK and prevent its association with the cyclin 
(7). 
The second family of inhibitors, CIP/KIP, inhibits a broad array of cyclin-CDK 
complexes (8) hence they are designated as universal CDKI. They interact with various 
CDK complexes, which eventually lead to inhibition of kinase activities of pre-activated 
Gl, cyclin E-CDK2, and cyclin D-CDK4/6. The CIP/KIP family includes p21, p27 and 
p57. Members of KIP proteins share a great deal of homology, e.g., p27 protein have a 
42% amino acid homology with p57 at amino terminal domain. The amino terminal 
domain mediates inhibition of CDK (10). 
P27 was originally identified as an inhibitor of CDK complex that is induced by 
antimitogenic signals (3, 25). Forced expression of p27 results in Gl-phase cell cycle 
arrest (9). Normally the progression of cell cycle Gl/S requires p27 proteolysis, which is 
initiated by the phosphorylation of p27 on threonine-187 (9, 10). 
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The p27 cyclin dependent kinase inhibitor 
P27 is a member of the universal cyclin dependent kinase inhibitor (CDKI) family 
and its gene was cloned in 1994 (26). P27 expression is regulated by cell contact 
inhibition and by specific growth factors such as transforming growth factor TGF-/3 (10). 
P27 has several functions such as tumor suppression, regulation of drug resistance in 
solid tumor, the promotion of apoptosis and cell differentiation. 
The cycle through which a cell moves as it divides and replicates itself is tightly 
regulated to control cell growth; cyclins and their partners, the cyclin dependent kinases 
(CDKs), are instrumental in driving the cell cycle forward. Cyclin D/CDK4 complexes 
function early in the cell cycle, while cyclin E/CDK2 complexes function later. P27 acts 
as an inhibitor of CDK2 activity and is required early in the cell cycle for the assembly of 
cyclin D1/CDK4 complexes. This suggests that p27 permits early progression but 
suppresses later progression of the cell cycle (11). 
P27 was first identified in cells treated with transforming growth factor (TGF-/3) 
or by stimulation of contact inhibition; under these conditions it was found as an inactive 
form bound to cyclin-E-CDK-2 (10,11). The protein was purified from a cyclin-E-CDK2 
affinity column and characterized by its strong inhibitory activity toward cyclin-E -
CDK2. P27 can directly inhibit the enzymatic activity of CDK-cyclin complexes and 
arrest cells in G1 (10). The association of p27 with CDK4- cyclin D or with CDK2-cyclin 
E complexes prevents phosphorylation of CDK4 on Threonine-172 and CDK2 on 
Threonine -160 via a CDK activated kinase (9, 10, 11). The level of p27 protein 
expression is high in G0/G1 resting cells and declines as cell progresses towards the S-
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phase. Overexpression of p27 has been shown to inhibit entry into the S-phase in normal 
and malignant cells (5). 
Mutation in genes encoding the KIP/CIP inhibitors p21 and p27 are rare. In 
mice, p27 behaves like a tumor suppressor. The loss of only one gene copy decreases the 
levels of p27 and susceptibility to cancer. The increase in levels of p27 in quiescent cells 
rapidly reduces after stimulation with mitogens (12, 13). 
Endothelin 
Endothelin (ET) is a potent vasoconstrictor/vasopressor peptide originally 
characterized from the culture supernatant of porcine aortic endothelial cells and consists 
of 21 amino acid residues with two sets of intrachain disulfide linkages (12, 13). 
Sequence analysis of the cloned cDNAs for porcine and human endothelin precursors 
showed that endothelin is produced in endothelial cells from a precursor of approximately 
200 residues (preproendothelin) (13,14). A presumptive 39 residue (porcine) or 38 
residues (human) is thought to be generated from preproendothelin. The amino acid 
sequences of the mature porcine and human endothelin are identical. Since its discovery 
in 1985 and its first detailed characterization in 1988, 3 ET isoforms have been described: 
ET-1, ET-2 and ET-3 (13). The vasoconstrictor potency is highest with ET-1. All ET 
isoforms are composed of 21 amino acids with two intrachain disulfide bridges. This 21-
residue (mature) endothelin is produced through unusual proteolytic processing of big 
endothelin between Trp21 and Val22 residues. A variety of cells including, vascular 
endothelial cells, heart, brain, spinal chord, pulmonary epithelial cells, glomerular 
mesangial cells, renal epithelial cells, monocytes and macrophages synthesize ET. After 
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biosynthesis, ET is released into the circulation or it diffuses towards the underlying 
vascular smooth muscles cells. ET-1 production in glomerular mesangial cells is 
stimulated by a variety of cytokines and growth factors, including IL-/3, TNF-a, TGF-/3, 
PDFG and vasopressin. Inhibiting factors include nitric oxide, prostacyclin and atrial 
natriuretic (14). 
Endothelins exert their effects by binding to two distinct cell surface receptors, 
ET-AR and ET-BR. These receptors are found on smooth muscle cells, myocytes and 
fibroblasts. The binding to the receptor leads to various cellular outcomes i.e. efflux of 
cellular calcium, release of intracellular stored calcium, and inhibition of Na/K ATPase 
(12, 13). The ET-BR binds the three peptides isotypes with equal affinity; in contrast, 
ETAR binds ET-1 with higher affinity than the other isoforms. Both receptors belong to 
the G-protein coupled receptor (GPCR) system and mediate biological responses from a 
variety of stimuli, including growth factors, vasoactive polypeptides, neurotransmitters, 
hormones and phospholipids (12). 
The physiological importance of the cleavage of big ET is indicated by the 
increase in vasoconstrictor potency. However the half-life of the cleavage product is less 
than a minute (12). It is rapidly removed from the circulation by the kidney, the lung and 
vascular endothelial cells. In addition to the potent vasoconstrictor and vasopressor 
actions, endothelin has been reported to produce a wide spectrum of biological effects 
including contraction of airway and intestinal smooth muscles, release of eicosanoids and 
/or endothelium derived relaxing factor from vascular beds, and inhibition of renin 
release from the glomerulus. It can stimulate the proliferation of vascular smooth muscle 
cells and fibroblasts. (4, 9, 13). 
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Recently, investigations into the role of the endothelin in mitogenesis have 
provided evidence of the importance of the ET-1 in cancer. Data suggest that ET-1 
participates in a wide range of cancer relevant processes such as cell proliferation, 
inhibition of apoptosis, matrix remodeling, bone deposition and metastases (12). ET-1 
stimulates DNA synthesis and cell proliferation in various cells including vascular 
smooth muscles, osteoblasts, gromerular mesangial cells, fibroblasts and melanocytes. 
ET-1 is also a mitogen for different cell types including prostate, cervical and ovarian 
cancer cells. In primary cultures and established ovarian carcinoma cell lines, 
spontaneous growth was significantly inhibited in the presence of antagonists, 
specifically the one which blocks ET-AR (15). The mitogenic activity of ET-1 can be 
amplified by synergistic interactions with other growth factors including epidermal 
growth factor (EGF), basic fibroblast growth factor (bFGF), platelet derived growth 
factor (PDGF), transforming growth factor and interleukin-6 (IL-6) (16). 
A specific ETA receptor, BQ123 is a well-characterized synthetic pentapeptide 
with high selectivity for the ETA receptor and thus high potency for ETA receptor 
antagonism (17). 
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Hypothesis and Purpose of Research 
A long term potential outcome of this line of investigation is to develop a 
potential therapy to increase cell proliferation in corneal endothelial cells. The proposed 
approach is to reduce the expression of p27 by transiently stimulating corneal endothelial 
cells with endothelin-1 (ET-1).We also investigated whether the specific ET-1 receptor 
antagonist, BQ123, may inhibit the suppression of p27. 
Primary cell culture of bovine corneal endothelial cells (BCECs), a widely 
used model of the corneal endothelium, will be used to determine whether the expression 
of p27 can be altered (reduced) in the presence of ET-1. We hypothesize that upon 
treatment with ET-1, the expression of p27 will decrease. If the expression of p27 is 
decreased, we expect that the cell cycle arrest will not occur, and the cells will continue 
to proliferate. This (decrease of p27), will be of potential therapeutic interest (at the 
moment the only way to correct damaged cornea is by transplantation, which is costly 
and has potential side effects). An agent that transiently inhibits p27 expression may be 
useful for treating an injured or diseased cornea by allowing replication of endothelial 
cells, and hence promoting healing of this tissue. 
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CHAPTER 2 
Materials and Methods 
Isolation and culture of bovine corneal endothelial cells (BCECs) 
Cow eyes were obtained from Kirby and Poe abattoir (Alvaton, Kentucky). The 
globe was placed cornea side up in a shallow dish lined with paper towel. A 2X antibiotic 
solution (from lOOx stock penicillin/streptomycin/ nystatin) was dropped on the globes 
and soaked for 30 minutes at room temperature after being covered with sterile gauze. 
The cornea was dissected with a l-2mm scleral rim and transferred endothelium side up 
to the eyecup and rinsed with dispase dissolved in Earle's Balanced Salt Solution (EBSS) 
(Invitrogen, CA). The cornea was incubated with dispase-EBSS at 37°C for 90 minutes. 
The endothelium was then gently scraped using spatula with a tapered silicon rubber tip. 
Cells were aspirated with a sterile Pasteur pipette and transferred to a sterile 15ml 
centrifuge tube containing 5ml of basal medium (Dulbecco's Eagle's Medium -DMEM) 
(Invitrogen, Carlsbad, CA) supplemented with 10% calf serum (Hyclone, Logan, UT) 
and 100/xl gentamycin, IOOJU.1 fungizone (antibiotic-antimycotic) and pelleted by 
centrifugation at 600xg for 2 minutes. The supernatant was decanted and the cell pellet 
resuspended with 5ml of basal media. Cells from two eyes were then transferred to a 
25cm2 culture flask (T25). The cultured cells were maintained in basal media in a 5% 
CO2, 37°C incubator. For subculture, cells were treated with trypsin (0.05% in calcium + 
magnesium with EBSS containing 0.6mM EDTA) and were pelletted by centrifugation at 
600xg for two minutes. The cell pellet was then resuspended in appropriate volume of 
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basal media and transferred to flasks. After the cells reached approximately 99% 
confluence, they were deprived of serum for twenty-four hours, some were treated with 
lOOnM ET-1, l j iM BQI23, combined (BQ123 + ET-1) and others left untreated i.e. they 
were not treated with either ET-1 nor BQI23 . 
Cell lysis and isolation of proteins 
BCECs were washed with cold EBSS, gently scraped from T25 flasks, and 
washed with ice cold phosphate buffered solution (4.38g NaCl, 1.38g NaP04 monobasic 
in 1 Liter) cells were then lysed with lysis buffer (20mM Hepes, 10% glycerol, 0.1 mM 
dithiothreitol (DTT), 1% tritox-lOOx and protease inhibitor cocktail) on ice for 30 
minutes with occasional rocking. The cell lysate was collected and sonicated on ice 2x 
for 10s, and the contents were aliquoted into 1ml tubes, and stored in a -20°C freezer for 
further analysis. The protein content was assessed by the Peterson modification of the 
Lowry protein assay using bovine serum albumin as a standard (18). 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis 
Cell lysates were solubilized in 5x solubilizing buffer (0.145M Tris, 0.025% 
bromophenol blue, 5% SDS, 25% glycerol) at a ratio of 1:4, and subjected to 90 °C for 
five minutes, followed by addition of beta-mercaptoethanol (BME) to a final 
concentration of 5%. Samples containing 20-40/il BCECs lysate were then analyzed by 
SDS-PAGE (Bio-Rad Laboratories, Hercules, CA). The 4-12% precast gradient gel was 
run at a constant voltage of 50V for three hours. The conditions of electrophoresis were 
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as described by Laemmli (29). Half of the gel was placed in coomasie blue stain to check 
for protein migration. Before transfer, the unit was assembled as follows: two sheets of 
whatman #1 paper and one sheet polyvinylidenedifluoride membrane (PVDF) were cut to 
8cm x 5cm. The PVDF membrane was carefully wetted in methanol (to remove 
hydrophobicity); the rest of the assembly unit then wetted with transfer buffer (1% SDS, 
20% methanol in lx running buffer (0.3g tris base + 1,44g glycine brought up to 1L with 
DI water) for at least 5 minutes. A blot sandwich was built on the sponge in the following 
order: Whatman paper, gel, PVDF, Whatman paper, each piece was layered on the 
sandwich. The sandwich was placed in such a way that proteins will migrate out of the 
gel and onto PVDF membrane. (PVDF side of the sandwich was towards the positive 
electrode). The separated proteins were then transferred from the gel to the PVDF 
membrane at a constant voltage of 30V overnight. The tank transfer blotting method was 
used to transfer proteins to the membrane. 
Immunodetection of proteins 
After overnight blotting, the PVDF membrane was removed from the transblot 
apparatus and placed in a flat dish and blocked with 5% non-fat dry milk (i.e. 25g non fat 
dry milk in 500ml lx PBS) for one hour at room temperature. The primary antibody 
rabbit anti-human p27 polyclonal antibody, (Zymed Laboratories, San Francisco, CA) 
was diluted at 1:100. In this case 6/d of antibody was added to 600[il of medium (PBS + 
0.1% Tween-20, i.e. PBS-T). The primary antibody was then added and the membrane 
was incubated for lhr, at 37°C. 30ml of PBS-T was then added to the dish while shaking, 
at 37°C for 5min, PBS-T was decanted and the process repeated until the sheet was 
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washed 6 times. To test for non specific binding, immunoblots were performed with the 
primary antibody omitted. 
The membrane was then incubated with secondary antibody. The experiment was 
performed independently using two sets of antibodies, goat anti-rabbit polyclonal 
antibody diluted at 1:500 conjugated to horseradish peroxidase (HRP) and goat anti-
rabbit polyclonal antibody (diluted at 1:200) conjugated to alkaline phosphatase (AP) 
(Southern Biotech, Birmingham, Alabama) was used. Secondary antibodies were added 
to the membrane in dish and incubated for lhr at room temperature with gentle shaking. 
The antibody was decanted and 30ml of PBS-T then added to the dish with gently 
shaking at 37°C for 5min. The PBS-T was decanted and the process repeated until the 
sheet has been washed six times at 5 minute intervals. The membrane was then treated 
with the enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech, 
Buckinghamshire UK). The ECL-treated membrane was exposed to a digital imager 
(Storm). In the second experiment the membrane was treated with enhanced 
chemi fluorescence (ECF) (Amersham Pharmacia Biotech, Buckinghamshire UK) and 
exposed to digital imager. 
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Results 
Protein concentration 
While the protein concentration in the lysate of ET-1 treated cells was highest, it 
was not statistically significant, i.e., protein concentrations of the cell lysate were 
2.90jag/(al for untreated BCEC, 3.10 (ig/(il in lOOnM endothelin-1 treated, 2.99pg/|al in 
BQ123 + endothelin-1 and 2.97 ng/^1 in BQ123 treated BCEC. 
Quiescent BCECs express p27 
Expression of p27 was determined by western blot analysis. When BCEC cells 
reached 90% to 99% confluence, they were placed in serum free medium for 24 hours 
and proteins harvested. 15 ug of total proteins were loaded on the second and lane while 
30|ag loaded on the 3rd lane the rest of the lanes were left (unloaded). A band below 28.8 
molecular weight marker consistent with p27 was obtained. As predicted, the band at 
approximately 27kDa was thicker in lane 3 (figure 1). 
Endothelin-1 downregulates p27 
To test for the expression of p27 in BCECs, confluent cells were placed in serum 
free medium for 24 hours. Some were left as control, (untreated) and the rest treated with 
lOOnM Endothelin-1 for a further 24 hours. 30jug of each sample was subjected to SDS-
PAGE on a 4-12%) gel and immunoblot analysis performed. The endothelin-1 treated 
cells showed a marked decrease in p27 expression (figure 2). 
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Non specific binding 
To test for possible non specific binding, two membranes from two experiments 
were compared. When cells reached 90% to 99% confluence, they were placed in serum 
free medium for 24 hours (left untreated), and sample subjected to SDS-PAGE on a 4-
12% gel and immunoblot analysis performed in the absence of primary antibody. Non 
specific binding to a protein between 75kDa and 48 kDa markers was observed in two 
experiments (figure 3). The band corresponding to p27 was absent. Although this does 
not prove the identity of the band as p27, it does show the observed band at 
approximately 27 kDa (figure 1) was not due to non-specific binding (presence of the 
secondary antibody) (figure 3). A positive control utilizing purified p27 protein was not 
performed. 
The effect of ET-1 Receptor antagonist (BQ123) is unclear 
To elucidate the role of Endothelin-1 receptor antagonist (BQ123), confluent cells 
were deprived of serum for twenty four hours (untreated) and then treated with lOOnM 
ET-1, or BQ123, or both combined (BQ123 +ET-1). 30(ag of each sample was subjected 
to SDS-PAGE on 4-12% gradient gel and immunoblot analysis performed. The 
expression of p27 seemed to be downregulated by BQ123, however a poor transfer of 
proteins to the membrane was observed (Figure 4). The experiment was repeated three 
times and Statistical analysis was performed with repeated-measures ANOVA, P=0.0026 
and post test Student-Newman-Keuls (SNK) (Figure 5). 
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Quiescent BCECs express p27 
A B 
1 2 3 4 5 1 2 3 4 5 
15jj.g protein 30|ig protein 
Figure 1 
Expression of P27 (determined by western blot). When BCEC cells reached 90% to 99% confluence, 
they were placed in serum free medium for 24 hours and proteins harvested. 
A: 15 (ig of total proteins loaded on the second lane while 30|ig loaded on the 3rd lane. The third lane has a 
thicker band. The left arrow shows 28.8 molecular weight markers 
B: Western blot analysis in the absence of primary antibody. There was absent of any band (except the 
molecular weight standards) when western blot analysis was performed in the absence of primary antibody. 
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Endothelin-1 treated and untreated BCEC culture 
t 
28.8MW 
^m jpMMB Unknown protein 
* p27 
Untreated Endothelin-1 treated 
Figure 2 
Effect of endothelin-1, on the expression of p27, when cells reached 90% to 99% confluence, they 
were placed in serum free medium for 24 hours. Some were left as control, (untreated) and the rest treated 
with lOOnM Endothelin-1 for a further 24 hours. 30|ig of each sample was subjected to SDS-PAGE on a 4-
12% gel and immunoblot analysis performed. 
Non specific binding 
26 
B 
1 2 3 4 5 
No p27 bands No p27 bands 
Figure 3 
To test for non specific binding the membranes were compared from two experiments 
A: When cells reached 90% to 99% confluence, they were placed in serum free medium for 24 hours (left 
untreated), and sample subjected to SDS-PAGE on a 4-12% gel and immunoblot analysis performed in the 
absence of primary antibody. 
Lane 1: 30ng, lane 2: 15|ig, lane 3: 30|ig, lane 4: 15|ig 
B: When cells reached 90% to 99% confluence, they were placed in serum free medium for 24 hours (left 
untreated), and sample subjected to SDS-PAGE on a 4-12% gel and immunoblot analysis performed in the 
absence of primary antibody. 
Lane 2: 15fj.g, lane3: 30|ig, lane 4: 0|ig protein, lane 5: 0|ug protein 
Right arrow: location of non specific binding (band). 
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Endothelin treated and receptor antagonist treated BCEC proteins 
1 2 3 4 5 
ET-I Untreated BQ123E BQ123 
Figure 4 
Expression o fp27 in BCEC treated with ET-1, BQ123+ET-1 and 1 jaM BQI23. When cells reached 
approximately 99% confluence, they were deprived of serum for twenty-four hours (untreated) and then 
treated with lOOnM ET-I, luM BQI23, both combined (BQ123+ET-1). 30 fig of each sample was subjected 
to SDS-PAGE on 4-12% gradient gel under reducing conditions, and immunoblot analysis performed. 
Lane2: cells treated with ET-1; lane3: control-untreated cells; Lane 4: cells simultaneously treated with 
ET-1 and BQ123; Lane 5: cells treated with BQ123. The left arrow represent 28.8 MW marker, while the 
right arrow shows unknown protein (a non specific binding between 75MW and 48 MW markers). 
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Figure 5 
Histograms represent relative levels of p27 determined by densitometry analysis of bands from 
western blots. 
All the immunoblot results were expressed as percentage relative to density of p27 bands (The 
volume in the spot as a percentage of the total volume*. The total volume equals the sum of the volumes of 
all the objects included in one quantitation) of all objects estimated using image analyzer. Histograms 
represent relative levels of p27 determined by densitometric analysis of bands from western blots. 
Statistical analysis was performed with repeated-measures ANOVA, P=0.0026 and post test Student-
Newman-Keuls (SNK) Bars: Control; mean + SD of data from three experiments, p<0.001 compared to 
BQ123, ET-1 and BQ123+ET-1. The expression o fp27 in BQ123 treated cells was not clear because 
proteins transfer efficiency to the membrane was low. 
T h e integrated intensity of all the pixels in the spot, excluding the background. To calculate volume, 
imageQuant subtracts the background value from the intensity of each pixel in the object, and then adds all 
the values. 
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CHAPTER 3 
Discussion 
It has been known that the ability for regeneration of corneal endothelium after 
injury, age or other stresses is limited in humans because this tissue is thought to be 
nonreplicating (19). However Joyce et al (6) have shown that corneal endothelial cells 
cease to move out G1 phase of the cell cycle, which means they have proliferative 
potential. This investigation explored ET-l 's role as a mitogenic factor in corneal 
endothelial cells and whether mitogenic activity is mediated through p27, a cyclin 
dependent kinase inhibitor. Previously it was shown in our lab by indirect 
immunofluoresce microscopy that p27 is present in bovine corneal endothelial cells 
(BCEC). Our observation by immunoblot analysis (Figure 1), though not clear, seems to 
suggest that p27 expression in BCEC was downregulated when the cells were treated 
with lOOnM endothelin-1. 
In this study, the role of ET-1 in the expression of p27 was investigated. The 
preliminary results presented here could suggest a novel mechanism whereby the 
expression of p27 was downregulated by ET-1. These effects were specific to 
Endothelin-1 treated cells as they were not observed in untreated cells (Figure 2). Though 
the action of ET-1 involves activation of signal transduction pathways, the specific action 
and/ or mechanism of ET-1 on p27 is unknown. However, the results suggest this 
mechanism might be due to the increased degradation of p27 in the cytoplasmic 
compartment (15). Earlier studies suggested that p27 degradation in mammals is 
mediated by both the ubiquitin proteosome pathway (21) and by ubiquitin-independent 
proteolytic cleavage (19). The ubiquitin pathway is emerging as a major mechanism that 
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regulates the selective and time control elimination of key short-lived proteins such as 
CKIs, this mechanism is achieved by phosphorylation of the target protein. In the case of 
p27, phosphorylation occurs on threonine-187 (19). In breast cancer cells, p27 
phosphorylation occurred almost exclusively in the cytoplasmic compartment, it probably 
reflects impaired nuclear import of p27 (19, 20). Taking this mechanism into account, the 
findings of this investigation raises the possibility that the effect of ET-1 binding to ETA 
receptor on the surface of B C E C may result in additional mechanisms which might have 
an impact on p27 protein. For example, the cytoplasmic phosphorylated p27 has been 
shown to bind to cytoplasmic proteins such as 14-3-3 protein, which prevents p27 nuclear 
export, consequently, there is no binding to cyclin D and eventually, the cell proliferates 
(20). 
Elucidating the function of ET-1 is crucial for cancer research; low level of P27 
protein due to the administration of ET-1 possibly stimulates cell division (cells enter S-
phase), which might coincide with the downregulation of p27 (figure 5). However, in this 
experiment the level of protein was not significantly different in ET-1 treated and 
untreated cells. Yang et al (22) could demonstrate that ET-1 alone was not able to 
increase smooth muscle cell proliferation. The ineffectiveness of ET-1 to stimulate 
smooth muscle cell proliferation was further confirmed by the result that ET-1 was not 
able to activate cyclin dependent kinase-2. Furthermore the CDK inhibitor, p27, was 
downregulated and the retinoblastoma protein, pRb, was not hyperphosphorylated, this 
being crucial for cell cycle progression (23). The indication is that the binding of ET-1 to 
the ETa receptor is responsible for potentiating its (ET-1) effects (30). However the 
relationship between ET-1 and the transforming growth factor TGF-J32 is well 
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documented. TGF-p2 which is present in the aqueous humor of the anterior chamber has 
been proposed to suppress mitotic activity of cells (19, 22). TGF-P2 exerts its 
antimitogenic effect through p27, and can inhibit both cyclin-D-CDK4 and cyclin-E-
CDK2. Expression and kinase activity of CDK2 enhanced by ET-1 increased 
significantly the cross sectional area and number of smooth muscle cell (19). 
It is necessary to point out however that in addition to the downregulation of p27 
by ET-1, our results suggest that BQ123 downregulates p27 (figure 5). This 
downregulation is intriguing because BQ123 is a receptor antagonist; there are several 
possibilities that can explain the effect of BQ123. First, BQ123 may contribute directly to 
the downregulation of p27 (figure 4) independent of receptor binding. Secondly, BQ123 
might prevent p27 localization to the nucleus, which is important for cytoplasmic 
degradation of p27. This needs further investigation because our results showed poor 
transfer of proteins (in BQ123 section) from the gel to the membrane. 
Considering the importance of the different biological functions of p27: regulation 
of cell growth, contact inhibition and apoptosis among others, the combined use of both 
ET-1 and BQ123 (figure 5) might be a useful tool to better characterize their roles in cell 
proliferation. Recent studies have shown that the expression levels of p27 are decreased 
in proliferating cells such as aggressive breast cancer cells (7). Taking into consideration 
the findings of this study, it could be possible that ET-1 stimulates uncontrolled 
proliferation of cells which might eventually commit the cell to a tumor. In contrast 
BQ123 affects the overall physiological activity of the cell which indirectly affects the 
regulation of p27. ET-1 is crucial in stimulating growth in various cancers. Therefore ET-
1 activity could account in generating tumor cells. Venuti et al (15) have previously 
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suggested a role for ET-1 in the regulation and promotion of cervical tumor growth. This 
growth promotion may result from the ability of ET-1 to act alone or with various growth 
factors such as EGF. 
Conclusion 
In conclusion, this study indicates that ET-1 may potentially play a role in 
promoting the regeneration of corneal endothelium after the cells are destroyed due to 
injury, disease or other stresses. This investigation suggests that the CDK inhibitor, p27, 
is functionally down regulated by the mitogen ET-1. However, the effect of its receptor 
antagonist BQ123 was unclear. ET-1 is important in BCEC cells moving out of Gl, and 
may be critical in the continuous proliferation of BCEC. Indeed, the pattern of p27 
expression suggests there could be other mechanisms, which regulate proliferating bovine 
corneal endothelial cells where ET-l 's role needs to be investigated further. 
Further studies 
The effect of Endothelin-1, BQ123 and BQ123 + ET-1 on the expression of p27 
in a cell may be a sign of mitogenic effect when they bind independently to and/or 
compete for ETA receptor. Though it is not clear how BQ123 could affect cell 
proliferation, our results indicate that BCEC responded to ET-1 treatment. Hence further 
investigation is required to determine whether the change in the expression of p27 in the 
presence of ET-1 and BQ123 is related to cell proliferation. 
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